|1.||Hurwitz, Herbert I: 45 articles (04/2015 - 01/2003)|
|2.||Reardon, David A: 34 articles (07/2015 - 02/2007)|
|3.||Friedman, Henry S: 33 articles (07/2015 - 02/2007)|
|4.||Wen, Patrick Y: 30 articles (06/2015 - 11/2008)|
|5.||Jonas, Jost B: 28 articles (09/2014 - 12/2006)|
|6.||Hainsworth, John D: 27 articles (01/2016 - 05/2005)|
|7.||Chamberlain, Marc C: 27 articles (10/2015 - 12/2006)|
|8.||Kurzrock, Razelle: 27 articles (08/2015 - 01/2010)|
|9.||Vredenburgh, James J: 26 articles (10/2015 - 02/2007)|
|10.||Desjardins, Annick: 26 articles (10/2015 - 02/2007)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
11/01/2011 - "We report an extremely aged patient case of metastatic colorectal cancer that was treated successfully with modified FOLFOX6 (mFOLFOX6) plus bevacizumab therapy. "
06/01/2011 - "Since the most frequent genetic alteration of colorectal cancer is KRAS mutation we have analyzed its effect on the efficacy of Avastin treatment. "
01/01/2012 - "Bevacizumab has an important role in first-line treatment of metastatic colorectal cancer. "
08/01/2013 - "Clinical studies have shown that bevacizumab beyond progression to first line therapy is beneficial for overall survival in advanced stage colorectal cancer. "
04/28/2015 - "The clinical application of bevacizumab in colorectal cancer is effective with good safety."
10/11/2012 - "GBM is a highly angiogenic tumor and several drugs are showing promise in clinical trials with one (bevacizumab), clinically approved for use. "
01/01/2004 - "Promising results have been obtained with bevacizumab (Avestin; Genentech, Inc.; South San Francisco, CA) in clinical trials in patients with a range of solid tumors; however, to maximize the potential of this agent, further research is needed to clarify a number of important issues. "
11/01/2015 - "Patients with tumors intersecting the ATR, IFOF, CST, or CC had significantly improved survival prognosis if they were additionally treated with bevacizumab. "
01/01/2015 - "Combining bevacizumab with different adjuvant therapies resulted in significant improvement of progression free survival (log hazard ratio, 0.87; 95% confidence interval (CI), 0.84-0.89), overall survival (log hazard ratio, 0.96; 95% CI, 0.94-0.98) and overall response rate (relative risk, 1.46; 95% CI: 1.33-1.59) compared to adjuvant therapy alone in all studied tumor types. "
11/01/2014 - "Bevacizumab significantly inhibited growth of A-431 tumors and caused a significant reduction in microvascular density and αvβ3 integrin expression within 7 d after start of therapy. "
|3.||Breast Neoplasms (Breast Cancer)
12/01/2013 - "In the metastatic setting, the efficacy of bevacizumab has been most extensively studied and demonstrated in patients with triple-negative breast cancer, the most difficult-to-treat population among patients with advanced disease and also the group with the biggest need for new treatment options. "
10/01/2008 - "The evolution of bevacizumab use in the first-line treatment of patients with breast cancer has been characterized by a logical progression of phase II and III trials that have demonstrated that angiogenesis plays an important role throughout all stages of breast cancer growth and progression. "
06/01/2015 - "Addition of four cycles of bevacizumab to D-FEC in HER2-negative early breast cancer significantly improved pathological complete response. "
09/01/2015 - "The improved overall survival with bevacizumab contradicts the findings of other studies of bevacizumab in breast cancer and may indicate the need for additional investigation of this agent. "
10/01/2013 - "Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens."
07/01/2013 - "To evaluate the efficacy of primary intra vitreal bevacizumab (IVB) injection on macular edema in diabetic patients with improvement in best corrected visual acuity (BCVA) and central macular thickness (CMT) on optical coherence tomography (OCT). "
01/01/2013 - "In Case 2, 2 TYE treatments combined with Avastin and Kenacort also improved her situation despite persistent macular edema with the best-corrected visual acuity further increasing to 6/7.5. "
05/01/2008 - "Treatment of macular edema secondary to CRVO with intravitreal bevacizumab injection of 1.25 mg was well tolerated and associated with marked macular thickness reduction and BCVA improvement in all patients. "
01/01/2015 - "Intravitreal TA therapy was beneficial in some patients with macular edema secondary to RVO that was refractory to intravitreal bevacizumab therapy. "
07/01/2013 - "Our short-term experience indicates that intravitreal administration of three doses of bevacizumab in one-month intervals between the doses leads to a significant reduction of macular edema and improvement of BCVA in patients with neovascular AMD."
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/01/2010 - "Bevacizumab is effective for the treatment of non-small cell lung cancer (NSCLC). "
04/01/2014 - "Currently bevacizumab is the only anti-angiogenic agent approved for the first-line treatment of non-small cell lung cancer (NSCLC) in selected patients. "
05/01/2014 - "Previous studies have demonstrated the efficacy of first-line bevacizumab combination therapy in advanced, non-squamous non-small cell lung cancer (NS-NSCLC). "
08/01/2010 - "Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study."
01/01/2014 - "Bevacizumab improves antitumor efficacy of CIK cells transfer therapy in non-small cell lung cancer (NSCLC). "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)